Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002962 (angina)
 21,142 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Cardiovascular disease in the form of coronary artery disease is the most common cause of death in western countries. Early treatment with stabilizing drugs and mechanical revascularization by percutaneous coronary intervention or coronary bypass surgery has reduced the mortality significantly. But in spite of improved treatments, many patients are still plagued by a high frequency of angina symptoms, hospitalizations and a poor prognosis. There is a need for new independent or supplementary biomarkers that can help to predict cardiovascular disease and cardiovascular events earlier and more precisely, and thus accompany existing biomarkers in both primary and secondary cardiovascular prevention. One such potential new biomarker is the protein YKL-40. As an independent biomarker in both cardiovascular diseases and noncardiovascular diseases, current evidence suggests YKL-40 to be most useful as a marker of disease severity, prognosis and short survival. However, future studies will evaluate whether YKL-40 can be used for monitoring of the treatment effect in different patient populations with a distinct disease diagnosis. In this article we explore present knowledge on YKL-40 as a biomarker in cardiovascular disease.
 ...
PMID:YKL-40: a new biomarker in cardiovascular disease? 2070 47

Coronary artery disease is the most common background of death in western countries. Medical therapies and revisualization by percutaneous coronary intervention or coronary by-pass surgery have reduced the mortality significantly. However, many of the treated patients still have angina or heart failure symptoms, many hospitalisations and a poor prognosis. Therefore, there is need for identifying new biomarkers, which alone or in combination with other risk markers are useful in monitoring treatment and as prognostic markers for future cardiovascular events in patients with ischemic heart disease. The inflammatory biomarker YKL-40 has recently been found elevated in patients with both acute and stable chronic cardiovascular diseases. Therefore, YKL-40 could potentially be a new useful biomarker of disease severity, prognosis and survival in patients with ischemic heart disease. The review will present published information about YKL40 in cardiac patients and discuss whether YKL-40 could be used for monitoring the therapies and for prognostic evaluations in patients with cardiovascular disease.
 ...
PMID:Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? 2160 7